Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. - Wikidata - awgldk - TriplyDB

Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

http://www.wikidata.org/entity/Q38092819

about

Development of allosteric modulators of GPCRs for treatment of CNS disorders Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS.mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex Motor Activity in Adult Patients with Attention Deficit Hyperactivity Disorder.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Update on treatments for dystonia.Mavoglurant as a treatment for Parkinson's disease.Promising therapeutic agents for the treatment of Parkinson's disease.Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand.Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation

P2860

Q34373958-634E92D1-E7FD-4B11-94DA-CFE986297393 Q35831877-D0D753F9-16F2-40AD-9AE8-4CC852F47D2D Q35867117-44800C70-81DA-4940-9F9B-4BCC7C9F3257 Q36205402-456985D8-8B00-429D-819D-D25648799E00 Q37506507-30651884-F2FD-48AA-AA7C-F074157E2EE7 Q38205381-DC75BB87-4CC2-469A-A42E-2BF70A0BB91A Q38222814-01C28EC6-1A96-46F8-9D21-A7376F613BC4 Q38767711-054F0AF0-F5C4-4A9C-BA1E-87CFDD7CB1BB Q40973806-8650A965-7EE2-4F88-9CFC-65DBB9E7FD00 Q46771818-7573EC69-AD9E-4B12-ABBA-64049310F6E7 Q57816814-F3981D71-2D98-4F9E-B240-68392CB12CFA

P2860

Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

http://www.wikidata.org/entity/Q38092819

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic potential of targe ...... ptors for Parkinson's disease.

@en

type

label

Therapeutic potential of targe ...... ptors for Parkinson's disease.

@en

prefLabel

Therapeutic potential of targe ...... ptors for Parkinson's disease.

@en

P1433

Q38092819-EFB618AD-FF4E-4AAE-A01C-2A7E1F9E841B

P1476

Q38092819-29E0015D-E235-4FBF-971A-F8142429BEB9

P2093

Q38092819-6285E436-1ECC-4E54-A048-2E421B6BEF98

P2860

Q38092819-04A37CBD-9EAB-4800-81A2-290507E52600

Q38092819-05B78926-0071-4A40-BC67-4C6611287D2B

Q38092819-0E5EC611-793F-444C-AF23-56366DC39FDB

Q38092819-10376487-646C-46C7-9928-8B6DFDBD2644

Q38092819-1194C8A6-0C3F-4261-8734-FC3CD15034C1

Q38092819-12630DA4-093D-4F58-A978-967EC1B574B8

Q38092819-1A78D824-43A1-4E62-A520-7A0CBD2763F0

Q38092819-20463B3D-698E-475E-9111-9030F7D56649

Q38092819-205C76B9-ACF2-4CDB-B410-0F812DF34AB2

Q38092819-213A903B-D9F2-4FE3-B12D-D2B34788636C

P304

Q38092819-B09FAF45-D673-471E-A360-1F1E15AE5276

P31

Q38092819-4380414B-FE1F-4D33-AB64-96A68AE693F2

P356

Q38092819-BD5E77A0-7D5E-4A0D-AEBB-A5CA6AD7E917

P433

Q38092819-1CC2DB06-04AC-4D80-91FA-8890C2E238A7

P478

Q38092819-AA59F249-4477-4165-81EF-63D6A18A5AF9

P50

Q38092819-541D89F1-CE40-4424-A9F6-185AE0A3FA56

P577

Q38092819-BBA6E9EB-5D3F-4342-BBAC-9B2D22CFAAAE

P5875

Q38092819-251A112C-7B42-4063-A3AA-0A1D427D8D50

P698

Q38092819-8894DF9C-2916-451B-8D9E-3062F47DF63A

P921

Q38092819-6D4FBABF-065C-42D9-9816-DBD9119DF8DA

P932

Q38092819-A519A09D-B4D0-4673-9CBB-E6839633E13C

P356

P1433

Neurodegenerative disease management

P1476

Therapeutic potential of targe ...... ptors for Parkinson's disease.

@en

P2093

Jonathan W Dickerson

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.

Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment

The glutamate receptor ion channels

Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment

Metabotropic glutamate receptors in the basal ganglia motor circuit

Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS

Distinct functional roles of the metabotropic glutamate receptors 1 and 5 in the rat globus pallidus

Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

P304

221-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NMT.12.6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236078728

http://www.w3.org/2001/XMLSchema#string

P698

23526920

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3603000

http://www.w3.org/2001/XMLSchema#string